Latest Biologicals News

Algorae Pharmaceuticals has independently validated its AlgoraeOS v2 platform, confirming improved accuracy in predicting synergistic drug combinations involving CBD across cancer models.

Mesoblast has received a Biologics License Application filing number from the FDA for rexlemestrocel-L, targeting life-threatening bleeding in end-stage heart failure patients with LVADs, advancing its regulatory journey with orphan drug and RMAT designations.

Booster Investment Scheme 2's Private Land and Property Fund swung back to profit with NZD 1.3 million after tax for the year ended March 2026, despite net asset value slipping due to unit redemptions. The Fund’s investment portfolio remains concentrated in unlisted New Zealand agricultural and property assets, while its Manager faces unrelated FMA proceedings.

Mesoblast has drawn US$50 million from a new five-year facility that reduces its interest burden and retires expensive short-term debt, strengthening its financial position ahead of commercial expansion.

Paradigm Biopharmaceuticals has completed enrolment ahead of schedule in its pivotal Phase 3 trial for Zilosul®, enrolling 538 patients with knee osteoarthritis and maintaining its timeline for interim and final results.

ReNerve has appointed J4 Biologics as a second manufacturer for its Empliq range to meet growing hospital approvals and market demand, strengthening its supply chain and scaling production capacity.

dorsaVi reveals that integrating RRAM and neuromorphic computing into its sensor platform could halve sensor count and more than double battery life in lower-limb exoskeletons, positioning the company as a key intelligence partner in a $1.79 billion market.

Opthea Limited resumes ASX trading as it pivots to develop OPT-302 for lymphangioleiomyomatosis, outlining a disciplined 18-month staged clinical program backed by A$31.2 million in cash.

TruScreen Group reported a 42% increase in FY2026 sales driven by new market entries including India and Indonesia, alongside launching a large-scale cervical cancer screening program in Vietnam and submitting major UNITAID proposals.

Cryosite Limited delivered a robust 22% revenue increase and 28% EBITDA growth for the ten months to April 2026, powered by expanding clinical trial activity and infrastructure upgrades.

West Cobar Metals reports promising metallurgical results from its Salazar project, highlighting a potential low-cost scandium production route via atmospheric leaching and bioleaching. The findings reinforce Salazar’s strategic value amid rising global scandium demand and ongoing U.S. critical minerals engagement.

Bio-Gene Technology has raised A$3.21 million to complete critical safety studies for its novel insecticide Flavocide and ramp up production of its natural insecticide Qcide, advancing its path to commercialisation in multiple global markets.